Handelsbanken Fonder AB Grows Position in Boston Scientific Co. (NYSE:BSX)

Handelsbanken Fonder AB lifted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 7.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,555,456 shares of the medical equipment provider's stock after acquiring an additional 184,049 shares during the quarter. Boston Scientific makes up 0.9% of Handelsbanken Fonder AB's investment portfolio, making the stock its 14th largest position. Handelsbanken Fonder AB owned approximately 0.17% of Boston Scientific worth $228,253,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of Boston Scientific by 9.7% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock worth $115,000 after acquiring an additional 119 shares during the period. Adero Partners LLC grew its stake in shares of Boston Scientific by 3.3% during the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after acquiring an additional 120 shares during the period. Grove Bank & Trust grew its stake in shares of Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock worth $261,000 after acquiring an additional 122 shares during the period. PFG Investments LLC grew its stake in shares of Boston Scientific by 1.6% during the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after acquiring an additional 125 shares during the period. Finally, Stonegate Investment Group LLC grew its stake in shares of Boston Scientific by 1.6% during the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock worth $699,000 after acquiring an additional 126 shares during the period. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Sanford C. Bernstein increased their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Canaccord Genuity Group increased their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a report on Monday, December 9th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Thursday. Royal Bank of Canada increased their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Finally, Morgan Stanley increased their price objective on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $107.39.

Insider Buying and Selling

In related news, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. This trade represents a 22.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 153,640 shares of company stock worth $15,718,289 in the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.93 during trading on Friday, hitting $104.44. 5,512,880 shares of the stock traded hands, compared to its average volume of 6,033,932. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market cap of $154.12 billion, a price-to-earnings ratio of 83.55, a PEG ratio of 2.79 and a beta of 0.80. The firm's fifty day moving average is $97.69 and its 200-day moving average is $89.06. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.